Medtronic, a medical device manufacturer based in Minneapolis, Minnesota, received CE Mark approval from the European Union for its continuous glucose management system. The Sentrino glucose management system is the first monitoring tool that offers minimally invasive detection technologies for use in critical care environments.
The company’s Sentrino CGM System is designed to continually display the interstitial glucose value for a patient. In addition, the device provides real-time data on how glucose levels are changing in the body. This gives patients the ability to quickly and easily regulate their blood glucose levels through diet and exercise.
According to a press release by Medtronic, the Setrino CGM System can assist healthcare providers in managing clinical workflow in hospitals and critical care facilities. With the new glucose monitoring tools, healthcare providers have the ability to use event-based protocols instead of time-based measurement protocols. In a traditional facility, blood glucose level measurements are taken every four to six hours.
In prepared remarks, general manager and vice president Greg Meehan said, "Despite its many benefits, good glycemic control is difficult to achieve in the CCU, and that's why we developed Sentrino. Medtronic has a decade of CGM expertise, and we coupled it with extensive clinical research to develop the Sentrino CGM System for critically ill patients.” He continued, "Given the market need for CGM in CCU patients, we believe the market potential will exceed $1 billion globally."
The system is not for sale in the United States as of yet. According to Medtronic, the system is still under investigation by the FDA.